Lentiviral Insertional Mutagenesis Helps to Uncover the Mechanisms of Resistance to AZD9291 and CO-1686 in EGFR-Mutant Lung Adenocarcinoma

被引：0
|
作者：
Pirazzoli, Valentina [1 ]
Spinozzi, Giulio [1 ]
Tenderini, Erika [1 ]
Benedicenti, Fabrizio [1 ]
Calabria, Andrea [1 ]
Montini, Eugenio [1 ]
机构：
[1] HSR TIGET, Milan, Italy
来源：
MOLECULAR THERAPY | 2016年 / 24卷
关键词：
D O I：
10.1016/S1525-0016(16)33021-0
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
212
引用
收藏
页码：S83 / S83
页数：1
相关论文
共 22 条
  • [1] Investigations of covalent binding efficiency for third-generation EGFR irreversible inhibitors AZD9291 and CO-1686
    Qin, Zhen
    Sun, Xuebing
    Liu, Ye
    Du, Yunguang
    Wang, Miao
    Hu, Nan
    Zhang, Jiye
    Peng, Hao
    Wang, Lai
    Wei, Min
    Luo, Lusong
    [J]. CANCER RESEARCH, 2015, 75
  • [2] AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients
    Remon, Jordi
    Planchard, David
    [J]. FUTURE ONCOLOGY, 2015, 11 (22) : 3069 - 3081
  • [3] Mechanisms of Acquired Resistance to AZD9291 in EGFR T790M Positive Lung
    Oxnard, Geoffrey R.
    Thress, Kenneth
    Paweletz, Cloud
    Stetson, Daniel
    Dougherty, Brian
    Lai, Zhongwu
    Markovets, Aleksandra
    Felip, Enriqueta
    Vivancos, Ana
    Kuang, Yanan
    Sholl, Lynette
    Redig, Amanda J.
    Cantarini, Mireille
    Barrett, J. Carl
    Pillai, Rathi N.
    Cho, Byoung Chul
    Lacroix, Ludovic
    Planchard, David
    Soria, Jean Charles
    Jaenne, Pasi A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S207 - S207
  • [4] High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells
    Nanjo, Shigeki
    Ebi, Hiromichi
    Arai, Sachiko
    Takeuchi, Shinji
    Yamada, Tadaaki
    Mochizuki, Satsuki
    Okada, Yasunori
    Nakada, Mitsutoshi
    Murakami, Takashi
    Yano, Seiji
    [J]. ONCOTARGET, 2016, 7 (04) : 3847 - 3856
  • [5] Acquired resistance to afatinib plus cetuximab in EGFR-mutant lung adenocarcinoma may be mediated by EGFR overexpression and overcome by the mutant-specific EGFR inhibitor, AZD9291.
    Meador, Catherine B.
    Jin, Hailing
    de Stanchina, Elisa
    Pirazzoli, Valentina
    Ladanyi, Marc
    Wang, Lu
    Chen, Xi
    Eisenberg, Rosana
    Cross, Darren
    Pao, William
    [J]. CLINICAL CANCER RESEARCH, 2014, 20
  • [6] Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment
    Ham, Jun Soo
    Kim, Seokhwi
    Kim, Hee Kyung
    Byeon, Seonggyu
    Sun, Jong-Mu
    Lee, Se-hoon
    Ahn, Jin Seok
    Park, Keunchil
    Choi, Yoon-La
    Han, Joungho
    Park, Woongyang
    Ahn, Myung-Ju
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (01) : E1 - E4
  • [7] Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial–mesenchymal transition phenotype
    Jing Xu
    Xiaoting Zhao
    Dengfeng He
    Jinghui Wang
    Weiying Li
    Yinghui Liu
    Li Ma
    Mei Jiang
    Yu Teng
    Ziyu Wang
    Meng Gu
    Jianbin Wu
    Yue Wang
    Wentao Yue
    Shucai Zhang
    [J]. Journal of Cancer Research and Clinical Oncology, 2018, 144 : 1413 - 1422
  • [8] Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype
    Xu, Jing
    Zhao, Xiaoting
    He, Dengfeng
    Wang, Jinghui
    Li, Weiying
    Liu, Yinghui
    Ma, Li
    Jiang, Mei
    Teng, Yu
    Wang, Ziyu
    Gu, Meng
    Wu, Jianbin
    Wang, Yue
    Yue, Wentao
    Zhang, Shucai
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (08) : 1413 - 1422
  • [9] Efficacy of rociletinib (co-1686) in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) assessed with a plasma EGFR test
    Gadgeel, S.
    Soria, J. C.
    Goldman, J. W.
    Wakelee, H.
    Camidge, D. R.
    Yu, H.
    Varga, A.
    Solomon, B.
    Oxnard, G. R.
    Ou, S. H.
    Papadimitrakopoulou, V.
    Liu, S. V.
    Reckamp, K.
    Spira, A.
    Piotrowska, Z.
    Despain, D.
    Karlovich, C.
    Yurasov, S.
    Sequist, L. V.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S628 - S628
  • [10] Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.
    Oxnard, Geoffrey R.
    Ramalingam, Suresh S.
    Ahn, Myung-Ju
    Kim, Sang-We
    Yu, Helena Alexandra
    Saka, Hideo
    Horn, Leora
    Goto, Koichi
    Ohe, Yuichiro
    Cantarini, Mireille
    Frewer, Paul
    Lahn, Michael
    Yang, James Chih-Hsin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
123